Navigation Links
GBM -Ab EIA Auto-Immune Markers 013-GBM-48 Glomerular Basement Membrane

ProductsGBM -Ab EIA Auto-Immune Markers 013-GBM-48 Glomerular Basement Membrane
Company ALPCO Diagnostics
Item GBM -Ab EIA Auto-Immune Markers 013-GBM-48 Glomerular Basement Membrane
Features 
Description This Immunoscan Anti-GBM was developed to detect the presence of antibodies against the glomerular basement membrane. The information is clinically useful in diagnosing Goodpastures syndrome, where anti-collagen (IV) - a3 chain antibody formation along with glomerulonephritis and pulmonary hemorrhage are primary diagnostic parameters. Since there are several other conditions presenting with similar symptoms, developed independently from anti-glomerular basement membrane (GBM) antibodies, this test can help to differentiate between these autoimmune renal disorders. The antigen used in the test is the M2 subunit purified from the noncollagenous (NC1) domain of type IV collagen. This antigen is fully described in the review article Biology of Disease Goodpasture Syndrome: Molecular Architecture and Function of Basement Membrane Antigen (1). Recent studies have shown that all Goodpasture patients have antibodies directed against M2 and some patients have additional antibodies against other basement membrane constituents and/or other collagen IV domains. The use of this purified antigen does not give false positive results for patient specimens containing other autoantibodies to the GBM, in contrast to crude collagenase digests of the total GBM (2). Glomerulonephritis is a major cause of irreversible renal failure. Many forms of glomerulonephritis are caused by immunological mechanisms, whereby a person forms antibodies against his own tissue components (auto-immunity) (3). Dixon and coworkers (4, 5) showed that in one particular type of glomerulonephritis, originally described by Ernest Goodpasture in 1919 (6) and subsequently referred to as Goodpastures syndrome (7), the disease was caused by an antibody response against antigens present in the glomerular basement membrane (GBM). Thus the disease is sometimes referred to as anti-GBM mediated glomerulonephritis. While Goodpastures syndrome is a relatively rare condition, the disease is rapidly progressive and, unless treated, has a case-fatality rate of 75-90% (8). Immediate and correct treatment is necessary before kidney (and often lung) damage has progressed too far. In clinical practice the diagnosis and recognition of the disease is frequently delayed since it is unexpected. Clinical signs such as hemoptysis, precipitate anemia, pulmonary opacities at x-ray and/or oliguria are in a sense unspecific and common to a variety of disorders. Mild prodromal lung or kidney symptoms are often overlooked or masked by a precipitating infection. The Immunoscan Anti-GBM offered is based on ELISA methodology (15, 16). The test utilizes wells coated with purified GBM antigen. Diluted patient serum is applied to the well and incubated. If specific anti-GBM antibodies are present they will bind to the antigen. Unbound material is washed away and any bound antibody is detected by adding enzyme-labeled anti-human IgG, followed by a second washing step and incubation with substrate. A well containing anti-GBM antibody will develop a color, which can be quantified.
Info ALPCO DiagnosticsCall ALPCO Diagnostics to buy products (US and Canada only; other locations use number below) USACanada1-866-466-7731

Customer Service: (800) 592-5726
Web site: http://www.alpco.com

Related medicine products :

1. CIC (C1-q) EIA Auto-Immune Markers 001-EK-CIC Circulating Immune Complexes
2. GBM -Ab EIA Auto-Immune Markers 013-GBM-96 Glomerular Basement Membrane
3. Anti-PR3 EIA Auto-Immune Markers 013-PR3-48 Proteinase
4. Anti-MPO ANCA EIA Auto-Immune Markers 013-MPO-96 Myeloperoxidase
5. Anti-PR3 EIA Auto-Immune Markers 013-PR3-96 Proteinase
6. Anti-MPO ANCA EIA Auto-Immune Markers 013-MPO-48 Myeloperoxidase
7. ENA Screen EIA Auto-Immune Markers 012-MDKES1 Extractable Nuclear Antigens
8. Surgical Markers
9. TLS Surgical Markers
10. SQUEEZE-MARK Surgical Markers
11. Iso-Insulin EIA Diabetes and Obesity Markers 008-10-1128-01
The MULTI-LINK RX PENTA Coronary Stent Systems with new ACCESS-LINK Stent Design are indicated for improving coronary luminal diameter....
Take Performance to a Higher Level....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
FemoStop plus system is a femoral compression system for hemostasis management. It provides a comfortable and efficient "hands off method of compressing the femoral artery and vein after diagnostic ...
Medicine Products:
(Date:6/25/2017)... ... June 25, 2017 , ... CareSet Labs released the Root NPI ... This is a new, greatly improved version of the Doctor Referral teaming dataset commonly ... Fred Trotter and subsequently called the the “Doctor Referral Dataset” as released by Medicare ...
(Date:6/24/2017)... ... June 24, 2017 , ... Genes Advice, a new company ... Florida and Texas doctors' offices and clinics. This breakthrough testing is part of ... recognizes the role genes play in determining an individual's tolerance of and reaction ...
(Date:6/24/2017)... ... , ... The weather is heating up and the days are getting longer, ... aware that the summer months provide more than warmer temperatures that are perfect for ... negatively affected from direct exposure to the sun. When it comes to the security ...
(Date:6/23/2017)... ... June 23, 2017 , ... "The Better Care Reconciliation Act ... harm to people with all chronic conditions, including mental illnesses, while increasing the ... the Affordable Care Act (ACA) requirement that insurers cover pre-existing conditions, it does ...
(Date:6/23/2017)... ... 24, 2017 , ... Studies show evidence that carotenoids and antioxidants derived either ... in these patients. , But how often do ophthalmologists and optometrists in Sweden recommend ... risk of or with early symptoms of AMD? A study published recently ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... Calif. , June 9, 2017 AirXpanders, ... company focused on the design, manufacture, sale and distribution ... market on the progress of its commercial roll-out in ... now available in more than one hundred (100) medical ... AeroForm offers a needle-free alternative for women ...
(Date:6/7/2017)... , June 7, 2017 Endo International plc ... 7, 2017, the Hon. Joseph R. Goodwin , ... West Virginia , entered a case ... Pelvic Repair System Products Liability Litigation (the "MDL") that ... cases to provide expert disclosures on specific causation within ...
(Date:6/3/2017)... 3, 2017  Eli Lilly and Company (NYSE: ... from the Phase 3 MONARCH 2 study showed ... inhibitor, in combination with fulvestrant, significantly improved progression-free ... in women with hormone-receptor-positive (HR+), human epidermal growth ... have relapsed or progressed after endocrine therapy (median ...
Breaking Medicine Technology: